Compare CPAC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAC | ABUS |
|---|---|---|
| Founded | 1949 | 2005 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.5M | 875.7M |
| IPO Year | 2003 | 2008 |
| Metric | CPAC | ABUS |
|---|---|---|
| Price | $10.66 | $4.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $12.90 | $5.00 |
| AVG Volume (30 Days) | 55.2K | ★ 1.9M |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.24% | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $4.49 | N/A |
| Revenue Next Year | N/A | $783.24 |
| P/E Ratio | $19.78 | ★ N/A |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $5.20 | $3.04 |
| 52 Week High | $11.50 | $5.10 |
| Indicator | CPAC | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 55.46 | 59.30 |
| Support Level | $10.25 | $4.19 |
| Resistance Level | $11.29 | $4.71 |
| Average True Range (ATR) | 0.39 | 0.20 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 84.72 | 89.52 |
Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.